GlaxoSmithKline Up as Novartis Corporation Drops Generic Advair in U.S.; Novartis Hands Back U.S. Rights to VR315 to Vectura Limited

Reuters -- Novartis has handed back U.S. rights to a drug widely believed to be a generic version of GlaxoSmithKline's lung blockbuster Advair, reducing the risk of cheap copies in Glaxo's biggest market.